Catabasis Pharmaceuticals registers $75 million of stock for its IPO

Citigroup, Cowen, Oppenheimer and Wedbush PacGrow assist with offering

By Devika Patel

Knoxville, Tenn., May 13 – Catabasis Pharmaceuticals, Inc. will price its initial public offering of common stock with a 30-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $75 million of stock for the sale.

Citigroup and Cowen and Co. are the bookrunning managers. Oppenheimer & Co. and Wedbush PacGrow are the co-managers.

Proceeds will be used for clinical development, working capital and other general corporate purposes.

The pharmaceutical company is based in Cambridge, Mass. The company intends to list its common stock on the Nasdaq under the symbol “CATB.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.